SGP WAS fudging on Victrelis trial data. Right now VRUS is less than complete with the data they are releasing and it brings about suspicion. It may well turn out that VRVS has just what they claim to have. They are riding the wave of success, and VRTX has taken a big hit as a result. With more complete data VRUS could be the one taking the hit and VRTX could regain darling status. We'll just have to wait and see. At the very least, I'll give VRUS credit for making a great stride in the science of treating Hep C.